Feeling like your energy, body composition, and recovery just aren’t what they used to be? Tesamorelin and other growth hormone-releasing peptides work with your body’s own natural systems to support fat loss, lean muscle, improved sleep, and cellular repair, helping you turn back the clock from the inside out.
What Are Peptides?
Peptides are short chains of amino acids – the same building blocks that make up proteins – linked together by chemical bonds. While proteins may contain hundreds or thousands of amino acids, peptides are generally smaller, typically ranging from two to about fifty amino acids in length. Because of their small size, peptides can act as highly specific signaling molecules in the body, binding to receptors on cell surfaces to trigger precise biological responses. The human body naturally produces many peptides that serve as hormones, neurotransmitters, and growth factors, regulating everything from metabolism and immune function to tissue repair and aging.
What Are Growth Hormone Peptides and Secretagogues?
Among the most widely discussed compounds in regenerative and anti-aging medicine are those that stimulate the body’s own production and release of growth hormone (GH). Rather than introducing synthetic growth hormone directly, these agents work by signaling the pituitary gland – a small structure at the base of the brain – to produce and secrete more of the body’s natural GH. Growth hormone plays a central role in body composition, metabolism, bone density, muscle mass, fat distribution, and cellular repair.
This family of compounds can be broadly divided into three categories:
- Growth Hormone-Releasing Hormone (GHRH) analogs, which mimic the body’s own GHRH signal. Examples include tesamorelin, sermorelin, and CJC-1295.
- Growth Hormone-Releasing Peptides (GHRPs), which act through a separate receptor — the ghrelin/growth hormone secretagogue receptor (GHS-R) — to stimulate GH release. The core members of this family include GHRP-1 (a heptapeptide), GHRP-6 and GHRP-2 (hexapeptides), hexarelin (a hexapeptide), and ipamorelin (a pentapeptide).
- Non-peptide growth hormone secretagogues, which are small-molecule compounds that activate the same ghrelin/GHS receptor as GHRPs but are not peptides. Examples include ibutamoren (MK-677), also marketed under the name Nutrobal, and anamorelin, which was developed specifically for cancer-related cachexia. Because these are non-peptide molecules, they are orally active — a major practical distinction from the injectable peptides listed above.
The key difference between GHRH analogs and GHRPs/secretagogues is their mechanism: GHRH analogs work through the GHRH receptor pathway, while GHRPs and non-peptide secretagogues work through the ghrelin receptor pathway. Importantly, when used together, GHRH analogs and ghrelin-receptor agonists can produce a synergistic effect on GH release that is greater than either class alone.
Tesamorelin
Tesamorelin is a synthetic analog of the body’s natural growth hormone-releasing hormone (GHRH). It is the only peptide in this class that holds full FDA approval, indicated specifically for the reduction of excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy, marketed under the brand name Egrifta SV.
Mechanism of Action: Tesamorelin binds to and stimulates GHRH receptors on pituitary somatotroph cells, promoting the synthesis and pulsatile release of endogenous growth hormone. GH then acts on target tissues and stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH’s downstream effects.
Reported Benefits: Clinical trials have demonstrated that tesamorelin significantly reduces visceral adipose tissue, improves triglyceride levels, lowers C-reactive protein, and may improve carotid intima-media thickness – a marker of cardiovascular risk – without significantly affecting subcutaneous fat.
Side Effects: The most commonly reported adverse reactions include arthralgia, injection site reactions (erythema, pruritus, pain), peripheral edema, myalgia, and pain in extremities. Fluid retention, glucose intolerance, and elevated IGF-1 levels may also occur.
Contraindications: Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis (e.g., from surgery, radiation, or trauma), known hypersensitivity to the drug, and pregnancy.
Sermorelin
Sermorelin is a 29-amino-acid synthetic peptide that represents the shortest fragment of natural GHRH that retains full biological activity. It was previously FDA-approved for diagnostic testing and treatment of pediatric growth hormone deficiency, though it has since been discontinued from the commercial market.
Mechanism of Action: Like tesamorelin, sermorelin acts on GHRH receptors in the anterior pituitary to stimulate the natural production and release of growth hormone.
Reported Benefits: In clinical studies, sermorelin increased growth velocity in children with idiopathic GH deficiency and has been used off-label in adults to support improved body composition, sleep quality, and recovery. It is often favored for its physiologic approach to GH stimulation, as it preserves the body’s natural pulsatile GH release pattern and feedback mechanisms.
Side Effects: Sermorelin is generally well tolerated. The most commonly reported adverse events include transient facial flushing, pain at the injection site, and occasional headache or dizziness.
Contraindications: Sermorelin should not be used in patients with active malignancy or known hypersensitivity to the peptide. As with all GH-stimulating agents, caution is warranted in patients with diabetes or glucose intolerance.
CJC-1295
CJC-1295 is a modified synthetic analog of GHRH(1-29) that has been engineered with a drug affinity complex (DAC) allowing it to bind covalently to serum albumin after injection. This dramatically extends its half-life to approximately 6–8 days, compared to the minutes-long half-life of native GHRH.
Mechanism of Action: CJC-1295 activates the GHRH receptor on pituitary somatotrophs, just as sermorelin and tesamorelin do, but its prolonged half-life allows for sustained GH and IGF-1 elevation. Clinical studies in healthy adults showed that a single injection produced dose-dependent increases in GH levels lasting 6 or more days and IGF-1 elevations lasting 9–11 days. Notably, pulsatile GH secretion is preserved during CJC-1295 stimulation, with the primary effect being an increase in trough (baseline) GH levels.
Reported Benefits: Studies have demonstrated sustained increases in GH and IGF-1 with preserved pulsatility, suggesting potential utility for improving body composition, recovery, and metabolic parameters.
Side Effects: In clinical trials, CJC-1295 was generally well tolerated. Reported side effects included transient injection site reactions, flushing, and headache. As with other GH-stimulating agents, fluid retention and changes in glucose metabolism are potential concerns.
Contraindications: CJC-1295 is not FDA-approved and is used investigationally. The same general contraindications that apply to GH-stimulating therapies – active malignancy, pituitary dysfunction, pregnancy, and uncontrolled diabetes – should be observed.
GHRP-1
GHRP-1 is a synthetic heptapeptide (seven amino acids: Ala-His-D-βNal-Ala-Trp-D-Phe-Lys-NH₂) and the only seven-amino-acid member of the core GHRP family, which otherwise consists of hexapeptides. It was developed as a “second generation” growth hormone-releasing peptide and represents an important step in the evolution of the GHRP class.
Mechanism of Action: GHRP-1 acts on the ghrelin/GHS receptor (GHS-R1a) at both pituitary and hypothalamic levels to stimulate GH release. A key pharmacological distinction is that GHRP-1 releases GH through a calcium-dependent, cAMP-independent mechanism – unlike GHRH, which stimulates GH release through the adenylyl cyclase/cAMP pathway. This means GHRP-1 can produce additive GH release when combined with GHRH or cAMP-elevating agents, because the two pathways are mechanistically separate. Like other GHRPs, GHRP-1’s effects are inhibited by somatostatin and are dependent on extracellular calcium influx through voltage-dependent calcium channels.
Reported Benefits: GHRP-1 produces a dramatic, selective, and dose-dependent increase in GH secretion. In early human studies, intravenous GHRP-1 infusion at doses of 0.25–1.0 μg/kg produced mean peak GH concentrations of up to 63 μg/L without affecting LH, FSH, TSH, or ACTH – demonstrating a high degree of selectivity for GH release. Its GH-releasing activity is synergistic with GHRH, and it has been studied in GH-deficient children where it demonstrated significant GH responses.
Side Effects: GHRP-1 was well tolerated in clinical studies. As with other GHRPs, potential side effects include transient flushing and injection site reactions. Its effects on cortisol and prolactin appear to be minimal at standard doses, though less clinical data is available compared to the more extensively studied hexapeptides.
Contraindications: GHRP-1 is not FDA-approved and is used investigationally. Standard contraindications for GH-stimulating peptides apply, including active malignancy, pregnancy, and pituitary dysfunction.
Ipamorelin
Ipamorelin is a synthetic pentapeptide and a member of the growth hormone-releasing peptide (GHRP) family. It is notable for being the first GHRP-receptor agonist with selectivity for GH release comparable to that of GHRH itself – meaning it stimulates GH without significantly affecting other hormones.
Mechanism of Action: Ipamorelin binds to the ghrelin/GHS receptor (GHS-R1a) on pituitary and hypothalamic cells to stimulate GH release. Unlike other GHRPs such as GHRP-6 and GHRP-2, ipamorelin does not cause significant increases in ACTH, cortisol, or prolactin, even at doses more than 200-fold higher than the effective dose for GH release. This selectivity profile makes it unique within its class.
Reported Benefits: Preclinical studies have shown that ipamorelin promotes longitudinal bone growth and increases body weight in a dose-dependent manner. Its clean side-effect profile and GH selectivity make it an attractive option for patients seeking GH optimization without unwanted hormonal effects.
Side Effects: Ipamorelin is generally well tolerated. Potential side effects include transient headache, flushing, and injection site reactions. Because it does not significantly stimulate cortisol or prolactin, it avoids many of the side effects associated with less selective GHRPs.
Contraindications: Ipamorelin is not FDA-approved. Standard contraindications for GH-stimulating peptides apply, including active malignancy, pregnancy, and pituitary dysfunction.
Pralmorelin (GHRP-2)
Pralmorelin, also known as GHRP-2, is a synthetic hexapeptide and one of the most potent growth hormone-releasing peptides developed. It has been approved in Japan for diagnostic use in evaluating growth hormone secretion but is not FDA-approved in the United States.
Mechanism of Action: GHRP-2 acts as a synthetic agonist of the ghrelin receptor (GHS-R1a), stimulating GH release from the pituitary through both direct pituitary action and hypothalamic mechanisms. It also has modest effects on other hormones – it can stimulate small increases in prolactin, ACTH, and cortisol levels, with ACTH-releasing activity comparable to that of corticotropin-releasing hormone (CRH). GHRP-2 has also been shown to increase food intake in humans, consistent with its ghrelin-mimetic properties.
Reported Benefits: GHRP-2 produces robust, dose-dependent GH release and increases IGF-1 levels. It has been studied for potential applications in GH deficiency, age-related GH decline, and catabolic states.
Side Effects: Side effects may include increased appetite, transient increases in cortisol and prolactin, flushing, and injection site reactions. The stimulation of the hypothalamic-pituitary-adrenal (HPA) axis is a distinguishing concern compared to more selective peptides like ipamorelin.
Contraindications: Active malignancy, pregnancy, pituitary dysfunction, and uncontrolled diabetes are contraindications. Caution is advised in patients with Cushing’s syndrome or conditions sensitive to cortisol elevation.
GHRP-6
GHRP-6 is the original synthetic hexapeptide growth hormone secretagogue and was the first GHRP to be extensively studied in humans. It served as the template from which many subsequent GHRPs, hexarelin, and non-peptide GH secretagogues – including ibutamoren (MK-677) and anamorelin – were developed.
Mechanism of Action: GHRP-6 binds to the ghrelin receptor (GHS-R1a) at both pituitary and hypothalamic levels to stimulate GH release. Its GH-releasing activity is dose-dependent and reproducible across intravenous, subcutaneous, intranasal, and oral routes of administration. GHRP-6 also stimulates modest increases in prolactin, ACTH, and cortisol. Additionally, GHRP-6 and its analogs have been shown to interact with the CD36 scavenger receptor, which may mediate cardiovascular protective effects including anti-atherosclerotic activity observed in preclinical models.
Reported Benefits: GHRP-6 reliably increases GH secretion and IGF-1 levels. It has been studied for potential roles in GH deficiency, short stature, aging, obesity, catabolic states, and even dilated cardiomyopathy.
Side Effects: GHRP-6 is known to significantly increase appetite – a property shared with ghrelin. It can also cause transient increases in cortisol and prolactin, flushing, dizziness, and injection site reactions. The appetite-stimulating effect may be undesirable for some patients.
Contraindications: As with other GHRPs, GHRP-6 should be avoided in patients with active malignancy, pregnancy, pituitary dysfunction, and uncontrolled diabetes. Caution is warranted in patients prone to cortisol-related metabolic effects, particularly those with obesity or diabetes risk.
Hexarelin
Hexarelin is a synthetic hexapeptide and one of the most potent members of the GHRP family. Developed as a structural analog of GHRP-6, hexarelin has been extensively studied in both children and adults and is distinguished by its strong GH-releasing activity and its unique GH-independent cardiovascular effects.
Mechanism of Action: Hexarelin binds to the ghrelin/GHS receptor (GHS-R1a) at both pituitary and hypothalamic levels to stimulate GH release. Its GH-releasing potency is superior to that of GHRH and comparable to or greater than that of GHRP-6. Like other GHRPs, hexarelin’s GH-releasing activity is synergistic with GHRH and is only partially blunted – rather than abolished – by inhibitory influences such as somatostatin, glucose, and free fatty acids. In addition to its GHS-R1a activity, hexarelin interacts with the CD36 scavenger receptor on macrophages and adipocytes. Through CD36, hexarelin activates peroxisome proliferator-activated receptor gamma (PPAR-γ), promoting cholesterol efflux from macrophages, reducing foam cell formation, and suppressing atherosclerotic plaque development. In adipocytes, hexarelin’s CD36-mediated activity promotes mitochondrial biogenesis and a “fat-burning” phenotype by upregulating genes involved in fatty acid oxidation and thermogenesis – effects that are independent of GH release.
Reported Benefits: In clinical studies, hexarelin produced potent, dose-dependent GH release in short normal children, obese children, and adults. The GH response to hexarelin was consistently higher than the response to GHRH across these populations. In preclinical models, hexarelin significantly attenuated atherosclerosis in ApoE-knockout mice by improving lipid profiles (decreasing total cholesterol, triglycerides, and LDL-c while increasing HDL-c), suppressing macrophage oxidized-LDL uptake, and inhibiting the LOX-1/NF-κB inflammatory signaling pathway. Hexarelin also improved lipid metabolic aberrations and insulin sensitivity in non-obese insulin-resistant mouse models, reducing liver triglycerides and correcting abnormal body composition by decreasing fat mass and increasing lean mass.
Side Effects: Hexarelin stimulates modest, transient increases in ACTH, cortisol, and prolactin – effects that are shared with GHRP-6 and GHRP-2 but absent with the more selective ipamorelin. In a study comparing hexarelin to ghrelin, hexarelin’s stimulatory effects on prolactin, ACTH, and cortisol were significant but less pronounced than those of endogenous ghrelin. Notably, the ACTH- and cortisol-releasing activity of hexarelin is dramatically amplified in patients with Cushing’s disease, which has led to its investigation as a diagnostic tool for differentiating pituitary from ectopic ACTH-dependent Cushing’s syndrome. In a 4-month chronic administration study, hexarelin was well tolerated; the most commonly reported side effects were increased appetite and modest weight gain (approximately 2.4–2.7 kg), with no significant changes in blood counts, electrolytes, or liver function. Chronic hexarelin therapy also produced partial desensitization of the GH response over time. Hexarelin has been shown to decrease slow-wave sleep when administered at night, an effect thought to be mediated by shifting the GHRH/CRH balance in favor of CRH.
Contraindications: Hexarelin is not FDA-approved. It should be avoided in patients with active malignancy, pregnancy, pituitary dysfunction, and Cushing’s disease or syndrome (where its ACTH-stimulating effects are markedly amplified). Caution is warranted in patients with conditions sensitive to cortisol elevation. As with all GH-stimulating agents, IGF-1 and glucose should be monitored.
Ibutamoren (MK-677 / Nutrobal)
Ibutamoren mesylate, commonly known as MK-677 or by its trade name Nutrobal, occupies a unique position in this family of growth hormone-stimulating agents. Although it activates the same ghrelin/GHS receptor (GHS-R1a) as the injectable GHRPs described above, ibutamoren is not a peptide – it is a small, non-peptide molecule originally developed using GHRP-6 as a structural template. This critical distinction gives ibutamoren a major practical advantage: it is orally active, meaning it can be taken by mouth rather than requiring subcutaneous or intravenous injection. It is currently under clinical investigation (marketed as LUM-201 for pediatric GH deficiency) but is not FDA-approved for any indication.
Mechanism of Action: Ibutamoren binds to the ghrelin/GHS receptor at both the pituitary and hypothalamic levels, stimulating the release of endogenous growth hormone. Like the injectable GHRPs, its GH-releasing activity is synergistic with GHRH and is mediated in part through GHRH-dependent hypothalamic pathways. Importantly, ibutamoren enhances the body’s existing pulsatile pattern of GH secretion rather than creating a continuous, non-physiologic elevation – GH pulse height and trough levels increase while the natural pulse frequency is preserved. In clinical studies, once-daily oral dosing at 25 mg increased mean 24-hour GH concentrations by approximately 97% and raised serum IGF-1 levels into the normal range for young adults within 2–4 weeks of treatment.
Reported Benefits: Ibutamoren has been studied in multiple randomized, placebo-controlled trials across diverse populations. In healthy elderly adults, a landmark 2-year trial demonstrated that daily MK-677 significantly increased fat-free mass (by approximately 1.1 kg over 12 months), increased body cell mass, and restored GH and IGF-1 levels to those of healthy young adults. In obese males, 8 weeks of treatment produced a sustained increase in fat-free mass, a ~40% increase in IGF-1, and a transient increase in basal metabolic rate. In calorie-restricted healthy volunteers, MK-677 reversed diet-induced negative nitrogen balance – a marker of protein catabolism – suggesting potential utility in catabolic states such as post-surgical recovery, chronic illness, or prolonged caloric deficit. Studies in elderly subjects have also shown that MK-677 increases biochemical markers of both bone formation (osteocalcin, bone-specific alkaline phosphatase) and bone resorption, consistent with increased bone remodeling. Additionally, in GH-deficient adults and children, oral ibutamoren produced significant dose-dependent increases in GH and IGF-1 levels.
Side Effects: The most commonly reported side effects of ibutamoren include increased appetite (which typically subsides after the first few months), transient mild lower-extremity edema, and muscle pain. A consistent finding across clinical trials is an effect on glucose metabolism: fasting blood glucose levels increased by an average of approximately 5 mg/dL, and impaired glucose tolerance on oral glucose tolerance testing has been observed. In a large 12-month trial in Alzheimer’s disease patients, drug-related laboratory adverse events – primarily elevated blood glucose and glycosylated hemoglobin – occurred significantly more often in the MK-677 group than in the placebo group. Modest, transient increases in cortisol and prolactin have been reported, though these generally remain within normal ranges and do not persist with continued dosing. A Phase IIb trial in elderly hip fracture patients was terminated early due to a safety signal of congestive heart failure in a limited number of patients, highlighting the importance of careful patient selection and monitoring, particularly in elderly or cardiovascularly compromised individuals. Body weight gain (averaging ~2.7 kg over 12 months) has also been observed.
Contraindications: Ibutamoren is not FDA-approved for any indication. Given its effects on glucose metabolism, it should be used with particular caution – or avoided – in patients with diabetes, prediabetes, or insulin resistance. It is contraindicated in patients with active malignancy, congestive heart failure or significant cardiovascular disease, pregnancy, and pituitary dysfunction. As with all GH-stimulating agents, IGF-1 levels should be monitored and maintained within age-appropriate ranges.
Anamorelin
Anamorelin is the second orally active, non-peptide ghrelin receptor agonist discussed in this article. While ibutamoren was developed primarily for age-related GH decline and body composition, anamorelin was developed specifically to address cancer-related anorexia and cachexia – a devastating syndrome of progressive weight loss, muscle wasting, and appetite loss that affects up to 80% of patients with advanced cancer. Anamorelin is approved in Japan for the treatment of cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. It has not received FDA approval in the United States, though it has been reviewed by the FDA and is considered the most rigorously evaluated cancer cachexia agent to date.
Mechanism of Action: Anamorelin is a highly selective ghrelin receptor (GHS-R1a) agonist that activates pathways controlling appetite, body weight, and lean body mass. Like endogenous ghrelin, anamorelin stimulates appetite centrally through hypothalamic pathways, promotes GH secretion from the pituitary, increases IGF-1 and IGFBP-3 levels, and may exert anti-inflammatory effects that counteract the catabolic inflammatory cascade driving cancer cachexia. It is administered as a once-daily oral dose of 100 mg.
Reported Benefits: Anamorelin has been evaluated in multiple large randomized, double-blind, placebo-controlled trials. The landmark ROMANA 1 and ROMANA 2 trials enrolled a combined 979 patients with advanced non-small cell lung cancer and cachexia. Anamorelin significantly increased lean body mass and total body weight compared to placebo at all time points over 12 weeks, with benefits sustained through 24 weeks in the ROMANA 3 extension study. A meta-analysis of seven RCTs encompassing 1,944 patients confirmed that anamorelin significantly increased total body weight (mean difference 1.73 kg), lean body mass (mean difference 1.06 kg), and patient-reported quality of life compared to placebo. Similar results have been demonstrated in gastrointestinal cancers, including gastric and pancreatic cancer. Anamorelin also improved appetite-related symptoms and nutritional biomarkers such as prealbumin. However, a consistent finding across trials is that anamorelin did not improve physical function as measured by handgrip strength – a co-primary endpoint in the ROMANA trials and the principal reason the FDA did not grant approval.
Side Effects: The most commonly reported adverse effects of anamorelin include hyperglycemia and diabetes mellitus, elevated glycosylated hemoglobin, and gastrointestinal symptoms including constipation. A notable safety concern is cardiac conduction abnormalities: clinical trials have reported cases of first-degree atrioventricular block, prolonged QRS complex, and other electrocardiographic changes. An analysis of the Japanese pharmacovigilance database found a significantly elevated reporting odds ratio for conduction defects with anamorelin, with a median time to onset of 13 days, suggesting that frequent cardiac monitoring with electrocardiograms is advisable during the first 2–3 weeks of treatment. Other reported adverse events include peripheral edema, elevated liver enzymes (γ-glutamyl transpeptidase), and, less frequently, atrial fibrillation and hypertension.
Contraindications: Anamorelin should not be used in patients with congestive heart failure, recent myocardial infarction or angina, severe cardiac conduction disorders (such as complete atrioventricular block), moderate-to-severe hepatic impairment (Child-Pugh B or C), poorly controlled diabetes mellitus, or pregnancy. It should not be co-administered with strong CYP3A4 inhibitors (such as clarithromycin, itraconazole, voriconazole, ritonavir, or cobicistat) due to drug interaction risk. Active malignancy is not a contraindication for anamorelin – unlike the other compounds in this article – because it was specifically developed for use in cancer patients. However, as with all GH-stimulating agents, the theoretical risk of promoting tumor growth through GH/IGF-1 stimulation should be considered in the clinical context.
How the Oral Secretagogues Compare to the Injectable Peptides
Ibutamoren and anamorelin share the practical advantage of oral bioavailability, setting them apart from every injectable peptide discussed in this article. While tesamorelin, sermorelin, CJC-1295, GHRP-1, ipamorelin, GHRP-2, GHRP-6, and hexarelin all require subcutaneous injection, ibutamoren and anamorelin achieve GH and IGF-1 stimulation through simple once-daily oral dosing. However, the two oral agents serve different clinical purposes: ibutamoren is primarily studied for age-related GH decline, body composition, and catabolic states in otherwise healthy individuals, while anamorelin is specifically developed for cancer cachexia and is the only compound in this article designed for use in patients with active malignancy.
In terms of selectivity, neither oral agent matches ipamorelin’s clean hormonal profile. Both ibutamoren and anamorelin can increase appetite, and both affect glucose metabolism – though anamorelin carries the additional concern of cardiac conduction abnormalities not seen with ibutamoren. Among the injectable GHRPs, hexarelin stands out for its unique cardiovascular effects mediated through the CD36 receptor, while GHRP-1 is notable for its high GH selectivity in early human studies. GHRP-6 and GHRP-2 remain the most extensively characterized members of the injectable GHRP family, with well-documented effects on appetite, cortisol, and prolactin.
Important Safety Considerations for All Growth Hormone Peptides and Secretagogues
Regardless of which compound is used, there are shared safety considerations that apply across this entire class of therapies:
- Growth hormone is a known growth factor. Stimulating its production carries a theoretical risk of promoting the growth of pre-existing malignancies. All patients should undergo appropriate cancer screening before initiating therapy – with the exception of anamorelin, which is specifically indicated for use in cancer patients under oncologic supervision.
- GH-stimulating compounds can affect glucose metabolism, potentially worsening insulin resistance or precipitating diabetes in susceptible individuals. This concern is particularly relevant for ibutamoren and anamorelin, which have demonstrated consistent effects on fasting glucose and glucose tolerance across multiple clinical trials. Baseline and periodic glucose monitoring is essential.
- Fluid retention – manifesting as edema, joint stiffness, or carpal tunnel syndrome – is a class effect related to GH activity.
- IGF-1 levels should be monitored during therapy and maintained within age-appropriate reference ranges.
- Cardiac monitoring should be considered, particularly for anamorelin, which has been associated with conduction abnormalities.
- Many of these compounds are not FDA-approved for general anti-aging or body composition use. Their use in these contexts is considered off-label or investigational.
The Importance of a Concierge Physician in Peptide Therapy
Peptide therapies such as bremelanotide offer exciting potential, but they require the kind of attentive, personalized medical oversight that a concierge physician is uniquely positioned to provide. Unlike traditional practice models, a concierge physician maintains smaller patient panels, allowing for the dedicated time and accessibility needed to thoroughly evaluate each patient before initiating therapy – including comprehensive cardiovascular risk assessment, screening for contraindications, and a detailed review of concurrent medications for potential interactions.
With a concierge physician keeping a watchful eye over your care, dosing is carefully tailored to your individual needs, and adverse effects such as blood pressure changes or hyperpigmentation are caught early through proactive monitoring and direct, ongoing communication. Rather than navigating rushed appointments or delayed callbacks, patients benefit from the kind of responsive, relationship-driven care that ensures peptide therapy remains both safe and effective.
A concierge physician takes the time to understand your complete clinical profile and treatment goals, ensuring that therapies like bremelanotide are not only appropriate but optimized for your unique health picture. This level of individualized attention maximizes potential benefits while minimizing risks – the kind of care that simply isn’t possible without a physician who truly knows you and is readily available when questions or concerns arise.
Peptide therapy should never be undertaken without qualified medical supervision, and a concierge model offers the gold standard of that oversight.
Sources
The Growth Hormone-Releasing Activity of Hexarelin, a New Synthetic Hexapeptide, in Short Normal and Obese Children and in Hypopituitary Subjects. The Journal of Clinical Endocrinology and Metabolism. 1995. Loche S, Cambiaso P, Carta D, et al.
The Effect of Hexarelin on Growth Hormone (GH) Secretion in Patients With GH Deficiency. The Journal of Clinical Endocrinology and Metabolism. 1995. Loche S, Cambiaso P, Merola B, et al.
Adrenocorticotropin- And Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing Peptide, in Normal Subjects and Patients With Cushing’s Syndrome. The Journal of Clinical Endocrinology and Metabolism. 1997. Ghigo E, Arvat E, Ramunni J, et al.
The effect of chronic hexarelin administration on the pituitary–adrenal axis and prolactin. Clinical Endocrinology. 1999. Rahim A, O’Neill PA, Shalet SM.
Hexarelin Decreases Slow-Wave Sleep and Stimulates the Secretion of GH, ACTH, Cortisol and Prolactin During Sleep in Healthy Volunteers. Psychoneuroendocrinology. 2004. Frieboes RM, Antonijevic IA, Held K, et al.
Hexarelin Attenuates Atherosclerosis via Inhibiting LOX-1-NF-κB Signaling Pathway-Mediated Macrophage Ox-LDL Uptake in ApoE Mice. Peptides. 2019. Cheng XL, Ding F, Wang DP, Zhou L, Cao JM.
Implications of Ghrelin and Hexarelin in Diabetes and Diabetes-Associated Heart Diseases. Endocrine. 2015. Mosa RM, Zhang Z, Shao R, et al.
A Growth Hormone-Releasing Peptide Promotes Mitochondrial Biogenesis and a Fat Burning-Like Phenotype Through Scavenger Receptor CD36 in White Adipocytes. Endocrinology. 2007. Rodrigue-Way A, Demers A, Ong H, Tremblay A.
CD36-mediated Cholesterol Efflux Is Associated With PPARgamma Activation via a MAPK-dependent COX-2 Pathway in Macrophages. Cardiovascular Research. 2009. Bujold K, Rhainds D, Jossart C, et al.
Mechanisms of Action of a Second Generation Growth Hormone-Releasing Peptide (Ala-His-D-Beta Nal-Ala-TRP-D-Phe-Lys-Nh2) in Rat Anterior Pituitary Cells. Endocrinology. 1993. Akman MS, Girard M, O’Brien LF, Ho AK, Chik CL.
Effect of a New Synthetic Hexapeptide to Selectively Stimulate Growth Hormone Release in Healthy Human Subjects. The Journal of Clinical Endocrinology and Metabolism. 1989. Ilson BE, Jorkasky DK, Curnow RT, Stote RM.
Growth Hormone-Releasing Peptides. European Journal of Endocrinology. 1997. Ghigo E, Arvat E, Muccioli G, Camanni F.
Growth Hormone-Releasing Peptides and Their Analogs. Frontiers in Neuroendocrinology. 1998. Camanni F, Ghigo E, Arvat E.
Anamorelin in Patients With Non-Small-Cell Lung Cancer and Cachexia (ROMANA 1 and ROMANA 2): Results From Two Randomised, Double-Blind, Phase 3 Trials. The Lancet. Oncology. 2016. Temel JS, Abernethy AP, Currow DC, et al.
ROMANA 3: A Phase 3 Safety Extension Study of Anamorelin in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients With Cachexia. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2017. Currow D, Temel JS, Abernethy A, et al.
The Efficacy and Safety of Anamorelin for Patients With Cancer-Related Anorexia/Cachexia Syndrome: A Systematic Review and Meta-Analysis. Scientific Reports. 2023. Taniguchi J, Mikura S, da Silva Lopes K.
A Multicenter, Open-Label, Single-Arm Study of Anamorelin (ONO-7643) in Advanced Gastrointestinal Cancer Patients With Cancer Cachexia. Cancer. 2019. Hamauchi S, Furuse J, Takano T, et al.
Management of Cancer Cachexia: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2020. Roeland EJ, Bohlke K, Baracos VE, et al.
Anamorelin and Conduction Defects: A Literature Review and Analysis of the Japanese Pharmacovigilance Database. In Vivo. 2024. Yabuki N, Sako KI, Maeda T, Ide N.
Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome. Current Oncology Reports. 2024. Dev R, Amano K, Naito T, Del Fabbro E.
Anamorelin Efficacy in Non–Small‐Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. Journal of Cachexia, Sarcopenia and Muscle. 2025. Laird BJA, Skipworth R, Bonomi PD, et al.
Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study. Cancer Medicine. 2023. Takayama K, Takiguchi T, Komura N, Naito T.